Share on StockTwits

ResMed (NYSE:RMD) COO Robert Andrew Douglas sold 8,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $50.11, for a total transaction of $400,880.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

RMD has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of ResMed in a research note on Wednesday, June 11th. They now have a $55.00 price target on the stock. Separately, analysts at JPMorgan Chase & Co. upgraded shares of ResMed from a “neutral” rating to an “overweight” rating in a research note on Tuesday, June 10th. Finally, analysts at Northland Securities downgraded shares of ResMed from a “market perform” rating to an “underperform” rating in a research note on Tuesday, May 27th. They now have a $40.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the company. ResMed presently has an average rating of “Hold” and a consensus target price of $46.90.

ResMed (NYSE:RMD) traded up 1.28% on Wednesday, hitting $50.50. The stock had a trading volume of 1,221,954 shares. ResMed has a 1-year low of $41.52 and a 1-year high of $57.34. The stock has a 50-day moving average of $51.21 and a 200-day moving average of $47.25. The company has a market cap of $7.087 billion and a P/E ratio of 21.88.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Wednesday, April 23rd. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by $0.01. The company had revenue of $397.80 million for the quarter, compared to the consensus estimate of $401.00 million. During the same quarter in the previous year, the company posted $0.58 earnings per share. The company’s revenue for the quarter was up 3.7% on a year-over-year basis. On average, analysts predict that ResMed will post $2.49 earnings per share for the current fiscal year.

ResMed Inc, (NYSE:RMD) is a holding company for the ResMed Group.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.